<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Inhibition of prostate cancer cell growth by human secreted PDZ domain-containing protein 2, a potential autocrine prostate tumor suppressor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Tam, CW; Cheng, AS; Ma, RYM; Yao, KM; Shiu, SYW</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>Endocrinology, 2006, v. 147 n. 11, p. 5023-5033</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2006</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/54245">http://hdl.handle.net/10722/54245</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>Endocrinology. Copyright © The Endocrine Society.</td>
</tr>
</tbody>
</table>
Inhibition of Prostate Cancer Cell Growth by Human Secreted PDZ Domain 2 Protein, a Potential Autocrine Prostate Tumor Suppressor

C. W. Tam, A. S. Cheng, R. Y. M. Ma, K.-M. Yao, and S. Y. W. Shiu

Departments of Physiology (C.W.T., A.S.C., S.Y.W.S.) and Biochemistry (R.Y.M.M., K.-M.Y.), The University of Hong Kong, Hong Kong, China

A possible role of the PDZ domain-containing protein 2 (PDZD2) in prostate tumorigenesis has been suggested. Besides, PDZD2 is posttranslationally cleaved by a caspase-dependent mechanism to form a secreted PDZ domain-containing protein 2 (sPDZD2) with unknown functions in humans. In this study, we demonstrate the endogenous expression of PDZD2 and secretion of sPDZD2 in cancerous DU145, PC-3, 22Rv1, LNCaP, and immortalized RWPE-1 prostate epithelial cells. Inhibition of endogenous sPDZD2 production and secretion by DU145, PC-3, 22Rv1, and RWPE-1 cells via the caspase-3 inhibitor Z-DEVD-FMK resulted in increased cell proliferation, which was abrogated by treatment with exogenous recombinant sPDZD2. Whereas sPDZD2-induced antiproliferation in DU145, PC-3, and 22Rv1 cells, it induced apoptosis in LNCaP cells. The data suggest that endogenous sPDZD2, produced by caspase-3-mediated cleavage from PDZD2, may function as a novel autocrine growth suppressor for human prostate cancer cells. The antiproliferative effect of sPDZD2 was apparently mediated through slowing the entry of DU145, PC-3, and 22Rv1 cells into the S phase of the cell cycle. In DU145 cells, this can be attributed to stimulated p53 and p21\(^{CIP1/WAF1}\) expression by sPDZD2. On the other hand, the apoptotic effect of sPDZD2 on LNCaP cells was apparently mediated via p53-independent Bad stimulation. Together our results indicate the presence of p53-dependent and p53-independent PDZD2\(s\)PDZD2 autocrine growth suppressive signaling pathways in human prostate cancer cells and suggest a novel therapeutic approach of harnessing the latent tumor-suppressive potential of an endogenous autocrine signaling protein like sPDZD2 to inhibit prostate cancer growth. (Endocrinology 147: 0000–0000, 2006)

GLOBALY, PROSTATE CANCER has become the third most common cancer in men, with half a million new cases each year, amounting to about 10% of all male cancers (1). It is the most common cancer after skin cancer and is the second leading cause of cancer-related death in men in the United States. The emergence of prostate cancer as a public health problem in developed countries has put tremendous pressure on the health care system to provide new and effective treatments. Current understanding of cancer cell biology has allowed scientists to develop a rational approach to combat cancer cells by using a combination of anticancer drugs, which would inactivate and/or activate, respectively, multiple targets in cell growth-promoting and growth-inhibitory signaling pathways. Whereas there is significant research progress on understanding the signaling mechanisms of androgen, a key growth-promoting hormone, in prostate cancer initiation and progression, advanced prostate cancer patients still suffer from inevitable relapse of the disease after receiving the recommended treatment of androgen deprivation therapy (2). Besides androgen, various classical growth factors such as epidermal growth factor, IGF, and TGF\(\beta\) have also been implicated, mostly, in the activation of prostate cancer growth (3, 4). Notwithstanding, therapeutic targets identified by these more classical growth-regulatory pathways are still in the process of successful translation into clinical use. Clearly there is an unmet clinical need to develop other novel therapeutic agents that can act effectively alone and/or in combination with androgen deprivation therapy to halt or reverse the progression of advanced prostate cancer. Such demand has fueled the search for novel endo-/para-/autocrine growth-promoting and growth-inhibitory signaling pathways important in prostate cancer pathogenesis, which may yield new therapeutic agents or targets for antiprostate cancer drug discovery and development. Of note, the recent success in the identification and inhibition of Hedgehog-Gli signaling pathways in prostate cancer growth has indeed opened up a new therapeutic strategy for prostate cancer (5–8).

PDZ domain-containing protein 2 (PDZD2) (also named KIAA0300 (9), PIN-1 (10), PAPIN (11), activated in prostate cancer (AIPC) (12), and PDZ domain-containing protein 3 (PDZK3)), is a six-PDZ (for PSD95, Discs-large, and ZO-1) domain protein, which is expressed in multiple tissues (13). Although proteins containing PDZ domains have been shown to bind specific C-terminal protein sequences of transmembrane receptors or ion channels and is believed to be involved in mediating intracellular protein–protein interactions, protein scaffolding, and intracellular signaling (14, 15), the functions of PDZD2 in humans are yet unknown. Interestingly, a possible role of PDZD2 (AIPC) in prostate cancer

First Published Online July 27, 2006

Abbreviations: AIPC, Activated in prostate cancer; BrdU, 5-bromo-2′-deoxyuridine; FBS, fetal bovine serum; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; PARP, poly(ADP-ribose) polymerase; PDZD2, PDZ domain-containing protein 2; SDS, sodium dodecyl sulfate; sPDZD2, secreted PDZD2.

Endocrinology is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.
pathogenesis has recently been suggested by a significant increase in PDZD2 (AIPC) gene and protein expression in prostate cancer tissues (12). Besides, the protein has also been shown to be posttranslationally cleaved by a caspase-dependent mechanism to form a secreted PDZ domain-containing protein 2 (sPDZD2) (13). Taken together, it would be of interest to determine whether sPDZD2, a posttranslationally cleavage product of PDZD2 (AIPC), may act as a novel autocrine signal important in prostate cancer pathogenesis. In this report, we studied the expression of sPDZD2 in human prostate cancer cells as well as the actions and mechanisms of sPDZD2 on prostate cancer cell growth modulation.

Materials and Methods

Human cancerous/imortalized cell lines and recombinant sPDZD2 synthesis

Human prostate cancer cell lines LNCaP.FGC (CRL-1740), DU145 (HTB-81), PC-3 (CRL-1435), and 22Rv1 (CRI-2505) as well as a human papillomavirus 18 transformed human prostate epithelial cell line RWPE-1 (CRL-11609) were obtained from American Type Culture Collection (Manassas, VA). LNCaP and 22Rv1 cells were propagated in RPMI 1640 medium (Life Technologies, Inc., Grand Island, NY) supplemented with 1-glutamine and 10% fetal bovine serum (FBS) (Life Technologies), whereas DU145 and PC-3 cells were, respectively, propagated in Eagle’s MEM (Life Technologies) and F-12 (Ham) (Life Technologies) medium supplemented with 10% FBS. RWPE-1 cells were cultured in keratinocyte-serum free medium supplemented with 50 µg/ml bovine pituitary extract and 5 ng/ml human recombinant epidermal growth factor (Life Technologies). All cell lines were incubated at 37 °C with 5% CO2 humidified atmosphere. Recombinant human sPDZD2 was synthesized and purified as previously described using the IMPACT (Intein Mediated Purification with an Affinity Chitin-binding Tag)-CN system (New England Biolabs, Beverly, MA) (16).

Cell proliferation, viability, and apoptosis assays

DU145, PC-3, 22Rv1, and RWPE-1 cells (2 × 10^4/ml) were seeded in 96-well plates and incubated with or without 10^8, 10^9, and 10^7 µM purified recombinant sPDZD2 or vehicle control 0.2% m/m Tris-HCl (pH 8), 1 mM EDTA for 24 and 48 h before the cells were processed for cell proliferation studies. In separate sets of experiments, DU145, PC-3, 22Rv1, and RWPE-1 cells were incubated with 10 µM specific caspase-3 peptide inhibitor, Z-DEVD-FMK (BD Biosciences, San Diego, CA), 10 µM-specific caspase-8 peptide inhibitor, Z-IETD-FMK (BD Biosciences), 10 µM negative control peptide Z-FA-FMK (BD Biosciences), or vehicle for 24 and 48 h. In addition, DU145, PC-3, 22Rv1, and RWPE-1 cells were each co-incubated with 10 µM Z-DEVD-FMK and 10^8 or 10^7 µM sPDZD2 for 48 h. Cell proliferation was measured by a tetrazolium-based Cell Titer 96 AQueous assay kit (Promega, Madison, WI). Absorbance at 490 nm was recorded 3 h after 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) addition. The proliferation of the cells was also monitored by a cell proliferation ELISA 5-bromo-2-deoxyuridine (BrDU) (colorimetric) kit (Roche, Stockholm, Sweden), according to the manufacturer’s protocol. Cell viabilities of LNCaP, DU145, PC-3, 22Rv1, and RWPE-1 cells, incubated with or without 10^9, 10^8, and 10^7 µM purified recombinant sPDZD2 for 24 and 48 h, were measured by trypsin blue dye exclusion assays. The number of viable cells was counted using hemocytometers. Any apoptotic effect treated, under serum-free conditions, with or without 10^8 or 10^7 µM sPDZD2, in the presence or absence of 10^8 µM dihydrotestosterone for 24 h. After treatment, cells were harvested and any apoptosis was detected according to manufacturer’s instructions.

Immunoblot analyses

For studies on the expression of PDZD2 and sPDZD2, PBS-washed native cancerous or immortalized prostate epithelial cells were incubated in their respective culture media without any added FBS for 24 h before the cells and conditioned media were collected for immunoblotting with the rabbit anti-PDZD2 antibody, which has been described previously (13). To study the effect of caspase inhibitors, the cells were incubated with or without 10 µM caspase-3 inhibitor Z-DEVD-FMK, 10 µM caspase-8 inhibitor Z-IETD-FMK, or 10 µM negative control peptide Z-FA-FMK under serum-free conditions for 48 h before immunoblotting analysis. For studies on the effects of sPDZD2 on the expression of proteins involved in cell cycle and apoptosis control, prostate cancer cells were harvested in lysis buffer (10 mM Tris-HCl (pH 7.4), 1% sodium dodecyl sulfate (SDS)) after they had been incubated with or without sPDZD2 for different time intervals. Lysates in sample buffer [0.2% SDS, 10% glycerol, 0.06 M Tris-HCl (pH 6.8), 100 mM dithiothreitol, and 0.01% bromophenol blue] were heated at 95°C for 5 min. Proteins in the conditioned media and recombinant sPDZD2 protein standards (10^12 to 10^17 M) were concentrated 50-fold using YM-10 Centricon (Millipore, Bedford, MA). Samples (10 µg) were resolved by SDS-PAGE and elec-troblotted to polyvinyl difluoride membranes (Millipore). The blots were blocked with 5% nonfat milk powder in TBS-T for 1 h at room temperature and then incubated with rabbit anti-PDZD2 antibody (1:10,000 dilution) overnight at 4°C. After washing with TBS-T, the blots were incubated with secondary antibodies against rabbit IgG (Zymed Laboratories, San Francisco, CA) and the signals were visualized by enhanced chemiluminescence Western blotting system (Amer sham Biosciences, Piscataway, NJ).

To study the expression of p21(CIP1/WAF1), p27(KIP1), cyclin B, cyclin D, Bad, poly(ADP-ribose) polymerase (PARP), and p53 as well as the phosphorylation status of p53, the blots were incubated with primary antibodies against p21(CIP1/WAF1) (1:500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA), p27(KIP1) (1:500 dilution; Santa Cruz Biotechnology); cyclin B (1:500 dilution; Santa Cruz Biotechnology); cyclin D (1:1,000 dilution; Santa Cruz Biotechnology); Bad (1:500 dilution; Santa Cruz Biotechnology); PARP (1:500 dilution; Santa Cruz Biotechnology); p53 (1:500 dilution; Santa Cruz Biotechnology); or primary phospho-p53 antibodies against Ser9, Ser15, Ser20, Ser37, Ser46, and Ser392 phosphorylation sites (1:100 dilution; Cell Signaling Technology, Beverly, MA) overnight at 4°C. After washing with TBS-T, the blots were incubated with secondary antibodies against mouse IgG (Amer sham Biosciences) for p21(CIP1/WAF1), p27(KIP1), cyclin B, cyclin D, Bad, PARP, and p53 antibodies or secondary antibodies against rabbit IgG (Zymed Laboratories) for phospho-p53 antibodies. Blots were stripped in 25 mM glycine buffer (pH 2.0) for 30 min for reprobing with α-tubulin (1:1,000 dilution; Santa Cruz Biotechnology). The signals were visualized by enhanced chemiluminescence Western blotting system (Amer sham Biosciences), and densitometric analyses of the developed blot normalized against α-tubulin were performed.

Transient reporter assay

DU145 cells (5 × 10^3/ml) were seeded onto 24-well plates. After 24 h, the cells were transiently transfected with Fugene 6 reagent (Roche). To each well, a mixture of 0.6 µl Fugene 6, 0.2 µg p21(CIP1/WAF1) reporter construct pGL3-p21pro or p27(KIP1) reporter construct pGL3-p27pro, and 0.04 µg Renilla luciferase reporter pRL-tk (Promega) were added. sPDZD2 (10^8, 10^9, and 10^7 M) or vehicle was added directly to the medium at one tenth dilution 24 h after transfection. After 24 and 48 h of incubation, Dual-Luciferase reporter assay system (Promega) was used to measure both the firefly and Renilla luciferase activities, according to the manufacturer’s instructions. Briefly, the cells were washed twice with PBS. Passive lysis buffer was added to each well and was shaken at room temperature for 15 min. Lysate (20 µl) from each sample was transferred to a 96-well plate for firefly and Renilla luciferase activity measurement by the microplate luminometer LB96V (EG&G Berthold, Bad Wildbad, Germany).

RNA preparation and semiquantitative RT-PCR analyses

Total RNA was extracted from DU145 cells treated with or without 10^9, 10^8, and 10^7 M sPDZD2 for 24 h using TRIzol (Invitrogen,
Carlsbad, CA), and the RNA (500 ng) was then reversely transcribed into cDNA by the SuperScript III first-strand synthesis system (Invitrogen) following the manufacturer’s instructions. p21CIP1/WAF1 cDNA was amplified by PCR using specific forward primer 5'-CCGATGGAACCTGCACACAGAACAG-3' and reverse primer 5'-GGGCTTCTCCCTGGAGAGAAT-3' designed from published p21CIP1/WAF1 cDNA sequence as reported previously (17). Similarly, p27KIP1 cDNA was amplified by PCR using specific forward primer 5'-CCAGGAGGTTAACCACCGG-3' and reverse primer 5'-GTCTGCTCCACAGAACAGGGG-3' designed from published p27KIP1 cDNA sequence as described previously (18). Glycerinaldehyde-3-phosphate dehydrogenase cDNA was amplified by PCR using specific forward primer 5'-CCAGGGGACACCCAGGG-3' and reverse primer 5'-GCCAGCCCCAGCTCAAG-3'. cDNA amounts and cycle numbers were optimized to ensure that amplification was within the linear range for quantitative analysis. The PCRs contained 2 μl cDNA, 1 pmol/μl primers, 1 μM deoxynucleotide triphosphate, 1× PCR buffer, 5 μM MgCl2, and 1 U Taq DNA polymerase. The 40 cycles of PCR amplification were preceded by denaturation at 94°C for 2 min. Each PCR cycle consisted of denaturation at 94°C for 15 sec, annealing at 55°C for 30 sec, and extension at 70°C for 1 min. After the reaction, 10 μl of the PCR products were separated on an agarose gel [1.5% (wt/vol)]. The amplified p21CIP1/WAF1 and p27KIP1 cDNAs, normalized against glycerinaldehyde-3-phosphate dehydrogenase cDNA in the same preparations, were quantitated.

Flow cytometry

Exponentially growing cells DU145, PC-3, and 22Rv1 were seeded in 25-cm² flasks at approximately 90% confluence. Cells were maintained at full confluence for 24 h to synchronize cells at early G1. Cells were then released into cell cycle progression by replating onto new 25-cm² flasks, at approximately 30% confluence, in respective cell culture media with or without 10-7 M sPDZD2. The cells were harvested at specific time points, fixed in ethanol (70%, vol/vol) overnight, and treated with RNase (10 mg/ml). Propidium iodide (250 μg/ml) was then added to the samples, mixed, and incubated in the dark for at least 15 min. Flow cytometry was performed using the EPICS Elite ESP high-performance cell sorter (Coulter Electronics, Miami, FL). In separate sets of experiments, unsynchronized DU145, PC-3, and 22Rv1 cells were treated with the caspase-3 inhibitor Z-DEVD-FMK (10 μM) or the negative control peptide Z-FA-FMK (10 μM) for 24 and 48 h. The cells were then harvested as described above for DNA analyses. The raw data collected were analyzed by Modfit LT (version 2.0; Verity Software, Topsham, ME) to eliminate aggregated cells for determination of cell cycle distribution.

Statistical and data analysis

The data were analyzed with one-way ANOVA followed by Tukey’s test. Two group comparisons were analyzed by unpaired Student’s t test. The level of significance for all statistical analyses was set at P < 0.05.

Effects of caspase inhibitors on endogenous PDZD2 expression and sPDZD2 secretion and cell growth

Full-length PDZD2 protein, which exhibits close sequence homology to pro-IL-16, is processed and cleaved by a caspase-dependent mechanism to generate sPDZD2 (13). In light of the fact that cleavage of pro-IL-16 to form its corresponding secretory IL-16 cytokine is mediated by caspase-3 (19), it would be of interest to determine whether the proteolytic cleavage of full-length PDZD2 to its secreted protein sPDZD2 is caspase-3 dependent. DU145, PC-3, 22Rv1, and RWPE-1 cells were incubated for 48 h with 10 μM Z-DEVD-FMK (a specific inhibitor of caspase-3), 10 μM Z-IETD-FMK (a specific inhibitor of caspase-8), or 10 μM Z-FA-FMK (a negative control peptide). Treatment of DU145, PC-3, 22Rv1, and RWPE-1 cells with Z-DEVD-FMK for 48 h resulted in 40, 28, 44, and 50% reduction of sPDZD2 secretion into the respective conditioned media, compared with cells treated with Z-FA-FMK (Fig. 1B). Concomitantly, PDZD2 expression in DU145, PC-3, 22Rv1, and RWPE-1 cells showed respective 3-, 2-, 4.4-, and 3.7-fold increases, compared with Z-FA-FMK-treated cells (Fig. 1C). However, there were no changes in sPDZD2 secretion and PDZD2 expression after the cells were treated with the specific caspase-8 inhibitor Z-IETD-FMK (10 μM) for 48 h (data not shown). These data indicated that the proteolytic cleavage of PDZD2 is mediated by caspase-3.

To determine whether alterations in PDZD2 and sPDZD2 levels in inhibitor-treated cells are associated with any changes in the cell growth rate, we also monitored DU145, PC-3, 22Rv1, and RWPE-1 cell proliferation by MTS-based assays. Interestingly, there were significant (P < 0.01) increases in DU145 (20.1–22.7%), PC-3 (22.9–24.8%), 22Rv1 (23.4–26%), and RWPE-1 (20.9–24.2%) cell proliferation after the cells were treated with the caspase-3 inhibitor Z-DEVD-FMK (10 μM) for 24 and 48 h (Fig. 1, D–G). No changes in the proportion of cells in different cell-cycle phases were detected after treatment with the caspase-3 inhibitor for 24 and 48 h (data not shown). There were also no changes in the proliferation of the cells after 24 and 48 h treatment of 10 μM caspase-8 inhibitor Z-IETD-FMK (data not shown). To further examine whether the observed increases in cell proliferation were due to inhibition of sPDZD2 secretion, we tested the ability of exogenously applied recombinant sPDZD2 (16) to counteract the growth-promoting effects of the caspase-3 inhibitor. As shown in Fig. 1H, the increases in DU145, PC-3, 22Rv1, and RWPE-1 cell proliferation induced by caspase-3 inhibitor treatment were abolished by coincubating with 10-8 M sPDZD2. These results suggest that the antiproliferative effects were predominantly mediated by sPDZD2 instead of PDZD2.

Effects of recombinant sPDZD2 on cancerous and immortalized prostate epithelial cell growth

Recombinant sPDZD2 induced a significant (P < 0.001) concentration-dependent inhibition of cell proliferation in DU145, PC-3, and 22Rv1 cells (Fig. 2). No significant changes in RWPE-1 cell proliferation in response to recombinant sPDZD2 were observed (data not shown). Treatment of DU145 cells with 10-8 and 10-7 M sPDZD2 for 24 h resulted
Tam et al. • Prostate Cancer Growth Inhibition by Human sPDZD2
in, respectively, 25.8 and 29.9% decreases in cell proliferation (P < 0.001). Treatment of PC-3 cells with 10⁻⁸ and 10⁻⁷ M sPDZD2 for 24 h resulted in, respectively, 13.5 and 22.6% decreases in cell proliferation (P < 0.01). Treatment of 22Rv1 cells with 10⁻⁸ and 10⁻⁷ M sPDZD2 for 24 h resulted in, respectively, 12.7 and 15.4% decreases in cell proliferation (P < 0.001). On the other hand, DU145 cell proliferation exhibited 38.6 and 43.5% decreases (P < 0.001) after the cells were treated with 10⁻⁸ and 10⁻⁷ M sPDZD2, respectively, for 48 h. PC-3 cell proliferation exhibited 23.8 and 41.6% decreases (P < 0.001) after the cells were treated with 10⁻⁸ and 10⁻⁷ M sPDZD2, respectively, for 48 h. 22Rv1 cell proliferation exhibited 21.7 and 27.7% decreases (P < 0.001) after the cells were treated with 10⁻⁸ and 10⁻⁷ M sPDZD2, respectively, for 48 h (Fig. 2, A–C). Similar antiproliferative effects of sPDZD2 on DU145, PC-3, and 22Rv1 cells were also demonstrated using the Cell Proliferation ELISA BrdU (colorimetric) kit (Roche) (Fig. 2, D–F). No changes in DU145, PC-3, 22Rv1, and RWPE-1 viabilities were detected (data not shown).

**Effects of sPDZD2 on regulation of proteins involved in cell cycle control**

Given that sPDZD2 induced the strongest antiproliferative effects on DU145 cells, compared with PC-3 and 22Rv1 cells (Fig. 2), we selected DU145 as the principal prostate cancer cell model to explore the intracellular mechanisms that may mediate the growth-inhibitory effects of sPDZD2. DU145 cells were treated with 10⁻⁸, 10⁻⁷, and 10⁻⁶ M sPDZD2 for 48 h, and any sPDZD2-induced changes in the expression levels of p21⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰, p27⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰, p53, cyclin B, and cyclin D were monitored. As shown in Fig. 3A, treatment of DU145 cells with 10⁻⁹, 10⁻⁸, and 10⁻⁷ M sPDZD2 for 48 h did not result in any changes in the level of p27⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰. No changes in the expression of cyclin B and cyclin D were also observed (data not shown). However, sPDZD2 induced changes in p21⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰ and p53 in growth-inhibited DU145 cells (Fig. 3A). Treatment of DU145 cells with 10⁻⁸ and 10⁻⁷ M sPDZD2 for 48 h resulted in 4.5- and 4.4-fold increases in p21⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰, respectively. In correlation, DU145 cells treated with 10⁻⁸ and 10⁻⁷ M sPDZD2 for 48 h, respectively, exhibited 3.9- and 3.8-fold increases in p53 expression. Of note, increased p53 expression (1.4-fold) was detected in DU145 cells after the cells had been incubated with 10⁻⁸ M sPDZD2 for 12 h. Relative to p53, the rise (2.6-fold) of p21⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰ expression was delayed by 12 h in DU145 cells treated with 10⁻⁸ M sPDZD2 (Fig. 3B). To further elucidate the signaling mechanisms of sPDZD2 in DU145 cells, the phosphorylation status of p53 in response to sPDZD2 treatment was investigated. No significant changes in the phosphorylation status of p53 at Ser6, Ser9, Ser15, Ser20, Ser37, Ser46, and Ser392 phosphorylation sites were detected in DU145 treated with 10⁻⁸ and 10⁻⁷ M sPDZD2 for 1, 4, and 8 h (data not shown). On the other hand, no significant changes in p21⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰, p27⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰, cyclin B, and cyclin D expression were observed in PC-3 cells, which showed no p53 expression (data not shown). Similarly, no significant changes in p21⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰, p27⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰, p53, cyclin B, and cyclin D expression were detected in 22Rv1 cells (data not shown).

**Apoptotic effects of sPDZD2 on LNCaP cells**

Recombinant sPDZD2 did not induce any changes in the viabilities of DU145, PC-3, 22Rv1, and RWPE-1 cells. However, incubation of LNCaP cells with 10⁻⁷ M sPDZD2 for 24 h resulted in 26.2% decrease in cell viability (P < 0.001), whereas LNCaP cell viability exhibited 14.7 and 18.6% decreases (P < 0.001) after treatment with 10⁻⁸ and 10⁻⁷ M sPDZD2, respectively, for 48 h (Fig. 4A). The observed decreases in LNCaP cell viability in response to sPDZD2 were found to be due to apoptosis induction (Fig. 4B), as measured by cell death detection ELISA kit (Roche). Significant (P < 0.001) increases in absorbance at 405 nm, which reflects an increase in mono- and oligonucleosomes in the cell cytoplasm, were observed in LNCaP treated with 10⁻⁸ and 10⁻⁷ M sPDZD2 for 24 h. Because p53 is a key regulator of apoptosis besides cell cycle progression (20), we also monitored the expression of p53 and the phosphorylation status of p53 at Ser15, Ser20, Ser37, and Ser46 phosphorylation sites, which are important in apoptosis control (21), in LNCaP cells. Treatment of the cells with 10⁻⁸ and 10⁻⁷ M sPDZD2 for 1, 2, and 4 h did not induce any changes in p53 levels and in its phosphorylation status at Ser15, Ser20, Ser37, and Ser46 (data not shown). Interestingly, treatment of LNCaP cells with 10⁻⁸ and 10⁻⁷ M sPDZD2 for 24 h resulted in respective 3.7- and 3.1-fold up-regulation in Bad expression. In addition, treatment of LNCaP cells with 10⁻⁸ and 10⁻⁷ M sPDZD2 for 48 h increased the expression of Bad by 2.6- and 2.1-fold, respectively (Fig. 4C). The cleavage of PARP, which serves as an early specific marker of apoptosis, was also observed after treatment of LNCaP cells with 10⁻⁸ and 10⁻⁷ M sPDZD2 for 24 and 48 h (Fig. 4C). In the presence of 10⁻⁹ M dihydrotestosterone, the apoptotic effects induced by 10⁻⁸ and 10⁻⁷ M sPDZD2 were significantly reduced (data not shown), indicating that androgen may confer protection against sPDZD2-induced apoptosis in LNCaP cells.

**Effects of sPDZD2 on p21⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰ and p27⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰ transcription**

To determine whether the elevated p21⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰ protein expression was caused by an increase in p21⁰⁰⁰⁰⁻⁰⁰⁰⁰⁰⁰⁰⁰ gene tran-
scription induced by sPDZD2, we monitored \( p21^{CIP1/WAF1} \) promoter activity in DU145 cells in response to sPDZD2 treatment using luciferase reporter assays. Treatment of DU145 cells with 10\(^{-8}\) and 10\(^{-7}\) M sPDZD2 for 24 h resulted in, respectively, 1.4- and 1.8-fold increases (\( P < 0.01 \)) in \( p21^{CIP1/WAF1} \) promoter activity. Similarly, treatment of DU145 cells with 10\(^{-8}\) and 10\(^{-7}\) M

Fig. 2. Effects of sPDZD2 on prostate cancer cell proliferation. DU145 (A), PC-3 (B), and 22Rv1 (C) cells were treated with 10\(^{-9}\), 10\(^{-8}\), and 10\(^{-7}\) M recombinant sPDZD2 for 24 and 48 h. The effects of sPDZD2 on cell proliferation were monitored by MTS assays. The proliferation of DU145 (D), PC-3 (E), and 22Rv1 (F) cells treated with 10\(^{-9}\), 10\(^{-8}\), and 10\(^{-7}\) M recombinant sPDZD2 for 24 and 48 h was also monitored by cell proliferation ELISA BrdU (colorimetric) assays. Data are shown as mean \( \pm \) se. *, \( P < 0.01 \) and **, \( P < 0.001 \), compared with control.
Effects of sPDZD2 on cell cycle progression

The growth suppressive effects of sPDZD2 on DU145 cells were monitored by flow cytometry. Treatment of synchronized DU145 cells with $10^{-5}$ mM sPDZD2 delayed the entry of the cells to the S phase of cell cycle. Without sPDZD2 treatment, the synchronized DU145 cells reentered into S phase by 12 h after replating, as reflected by an increase in the percentage of S phase cells from 22.1 to 38.9% (Fig. 6A). In contrast, most of the sPDZD2-treated cells remained in the G0/G1 phase, and no significant increase in the percentage of S phase cells was observed until 48 h after replating (Fig. 6B). Similar to DU145 cells, untreated synchronized PC-3 and 22Rv1 cells reentered into S phase by 12 h after replating, as reflected by an increase in the percentage of S phase cells from 25.4 to 34.8% and from 25.4 to 33.7%, respectively, whereas most of the sPDZD2-treated PC-3 and 22Rv1 cells remained in the G0/G1 phase until 48 h after replating (data not shown).

Discussion

In this communication, we demonstrated the endogenous intracellular expression of PDZD2 and extracellular secretion of its cleavage product sPDZD2 in human prostate cancer LNCaP, DU145, PC-3, and 22Rv1 cell lines as well as the immortalized RWPE-1 cells (Fig. 1A). Furthermore, the cleavage of sPDZD2 from its precursor PDZD2 in prostate cancer cells is shown to be mediated by a caspase-3-dependent mechanism, similar to that reported for the proteolytic processing of IL-16 from pro-IL-16 (19) (Fig. 1, B and C). Importantly, inhibition of endogenous sPDZD2 production and secretion by DU145, PC-3, 22Rv1, and RWPE-1 cells via the specific caspase-3 inhibitor Z-DEVD-FMK resulted in increased cell proliferation, which can be abrogated by supplementation with exogenous recombinant sPDZD2 (Figs. 1, D–H). The results suggest that endogenous sPDZD2 may exert an autocrine physiological antiproliferative action on human prostate cancer cells. Although we estimated the concentration of endogenous sPDZD2 in the conditioned cell culture media to be in the range of $10^{-10}$ to $10^{-11}$ M, it remains to be determined whether this reflects the actual concentration of sPDZD2 in human interstitial fluid or plasma. Notwithstanding this limitation of the yet-unknown physiological concentration of sPDZD2, it is noteworthy that the predicted antiproliferative actions can indeed be induced in the cancerous prostate epithelial cells by treating them with recombinant sPDZD2 (Fig. 2), which provide support for our postulation that sPDZD2 may function as an autocrine growth suppressor for human prostate cancer cells. It is also evident from our studies that sPDZD2 can suppress prostate cancer cell growth by not only antiproliferation as shown in DU145, PC-3, and 22Rv1 cells but also apoptosis induction in LNCaP cells (Fig. 4). Together with the reported up-regulation of gene and protein expression of PDZD2, also known as AIPC, in human prostate cancer tissues (12), our data indicate that sPDZD2, a proteolytic secretory product of PDZD2, may indeed play an important role in growth dysregulation in prostate cancer tumorigenesis and progression.

Flow cytometric data have indicated that antiproliferative effects of sPDZD2 on DU145, PC-3, and 22Rv1 cells are largely mediated via slowing the entry of these cancer cells into the S phase of the cell cycle (Fig. 6). In DU145 cells, we found an increase in p53 protein expression, followed by correlative increases in the gene and protein expression of p21CIP1/WAF1, which is an important p53 transcriptional target (22) (Figs. 3 and 5). The observed slowing of DU145 cell cycle progression from G1 to S in response to sPDZD2 can thus be adequately explained by sPDZD2-induced up-regulated gene and protein expression of p21CIP1/WAF1, which is a well-known cyclin-dependent kinase inhibitor crucial for G1 mitotic checkpoint regulation (23). Interestingly, the DU145 cell line, in which more than 90% of the cells show positive immunoreactivity for p53 (24), carries two mutant p53 alleles producing p53<sup>223Leu</sup> and p53<sup>274Phe</sup>, whose transactivation abilities on p53-responsive genes differ from each other (25). It has been shown that p53<sup>223Leu</sup> was as active as wild-type p53 in transactivation of p53-responsive genes such as p21<sup>CIP1/WAF1</sup>, whereas p53<sup>274Phe</sup> has no detectable transactivation activity on those genes in a direct transactivation assay (25). Apparently sPDZD2 has the ability to activate p53<sup>223Leu</sup>-p21<sup>CIP1/WAF1</sup> signaling pathway in DU145 cells to mediate its cytostatic actions observed in the present study, although the remote possibility of p21<sup>CIP1/WAF1</sup> activation by p53-independent mechanisms may still need to be
FIG. 4. Effects of sPDZD2 on LNCaP cell growth. A, LNCaP cells were treated with $10^{-9}$, $10^{-8}$, and $10^{-7}$ M recombinant sPDZD2 for 24 and 48 h. The effects of sPDZD2 on cell viability were monitored by trypan blue dye exclusion assays. B, Cell death detection ELISA PLUS assay kit (Roche) was used to determine the apoptotic effects of sPDZD2 on LNCaP cells. After treatment of the cells with $10^{-8}$ and $10^{-7}$ M recombinant sPDZD2 for 24 h, the cells were lysed and the presence of nucleosomes in the cytoplasm was detected by measuring absorbance values at 405 nm. Data are shown as mean ± SE. **, $P < 0.001$, compared with control. C, LNCaP cells were treated with $10^{-9}$, $10^{-8}$, and $10^{-7}$ M recombinant sPDZD2 for 24 and 48 h. The level of Bad and the processing of PARP were monitored by immunoblotting.
considered in future studies. In an attempt to further define the mechanisms involved in p53 up-regulation and activation in DU145 cells by sPDZD2, we examined any sPDZD2-induced changes in phosphorylation at specific serine residues of p53 in DU145 cells, using a panel of antibodies against phospho-p53 (Ser6, Ser9, Ser15, Ser20, Ser37, Ser46, and Ser392). Intriguingly, we were unable to detect any significant sPDZD2-induced changes in p53 phosphorylation at the aforementioned serine residues in DU145 cells. Because active p53 is subject to a diverse array of covalent posttranslational modifications, any sPDZD2-induced changes in protein phosphorylation at sites outside those examined and in

**FIG. 5.** Effects of sPDZD2 on *p21CIP1/WAF1* and *p27KIP1* gene transcription. The promoter activities of *p21CIP1/WAF1* (A) and *p27KIP1* (B) were monitored by luciferase reporter assays after DU145 cells were treated with $10^{-9}$, $10^{-8}$, and $10^{-7}$ M recombinant sPDZD2 for 24 and 48 h. Data are shown as mean ± se. *, $P < 0.01$ and **, $P < 0.001$, compared with control. C, Total RNA was extracted from DU145 cells treated with or without $10^{-9}$, $10^{-8}$, and $10^{-7}$ M recombinant sPDZD2 for 24 h using TRizol (Invitrogen) and was reversely transcribed into cDNA by using the SuperScript III first-strand synthesis system (Invitrogen). After 40 cycles of amplification by PCR, the PCR products were separated by 1.5% agarose gel. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.
other modifications such as acetylation, ribosylation, O-glycosylation, ubiquitination, and sumoylation (21) will need to be examined in future studies.

Given that p53 is an important node that integrates diverse oncogenic and DNA damage signals to mediate cytostasis and apoptosis (26), we also examined whether p53 activation is likely to be a common mechanism through which sPDZD2 induces its antiproliferative or apoptotic effects on other prostate cancer PC-3, 22Rv1, and LNCaP cells. Of note, we could not detect any expression of p53 in the PC-3 cell line, which has been shown to harbor a frameshift deletion mutation in its single p53 allele, causing a stop signal at codon 169 of the protein (27). Moreover, sPDZD2 induced no significant changes of p21CIP1/WAF1 and p27KIP1 in PC-3 cells.

The above findings suggested that, distinct from DU145 cells, the mechanism mediating sPDZD2-induced antiproliferation in PC-3 cells is p53 independent. Similarly, no significant changes of p21CIP1/WAF1 and p27KIP1 in PC-3 cells. The above findings suggested that, distinct from DU145 cells, the mechanism mediating sPDZD2-induced antiproliferation in PC-3 cells is p53 independent. Similarly, no significant changes of p21CIP1/WAF1 and p27KIP1 in PC-3 cells.

In summary, we have obtained evidence to support the existence of PDZD2/sPDZD2-mediated autocrine growth suppressive signaling pathways in human prostate cancer cells. The p53-dependent and p53-independent mechanisms of sPDZD2 in growth inhibition of DU145, PC-3, 22Rv1, and LNCaP prostate cancer cell lines observed in our studies indicate that PDZD2/sPDZD2 signaling may use different and, perhaps, new signal transduction pathways of the intrinsic tumor suppressive network in prostate cancer in different developmental or progression stages to mediate its growth suppressor actions. Detailed characterization of these PDZD2/sPDZD2 signaling pathways and identification of the membrane receptor(s) involved may yield not only new therapeutic targets for antiprostate cancer drug discovery and development but also provide novel ways, such as harnessing therapeutically the latent tumor-suppressive potential of an endogenous autocrine signaling protein like sPDZD2, to inhibit prostate cancer growth. Besides the potential therapeutic implications mentioned above, unraveling the autocrine signaling mechanisms of PDZD2/sPDZD2 in prostate cancer growth suppression will help to increase our understanding of the physiological growth-inhibitory
networks contributed by vitamin D$_3$/vitamin D receptor (30) and melatonin/MT$_1$ receptor (31–34) signaling at the endocrine level and fatty acid metabolites/peroxisome proliferator-activated receptor-γ (35, 36) signaling at the paracrine level.

Acknowledgments

Received February 16, 2006. Accepted July 20, 2006.

Address all correspondence and requests for reprints to: Dr. Stephen Y. W. Shiu or Dr. K.-M. Yao, Department of Physiology/Biochemistry, The University of Hong Kong, Laboratory Block, Faculty of Medicine Building, 21 Sassoon Road, Hong Kong, China. E-mail: syshiu@hkucc.hku.hk or km Yao@hku.hk.

This work was supported by Research Grants HKU7474/04M (to K.-M.Y.), HKU7580/05M and the Neuroendocrinology Research Fund (to S.Y.W.S.). C.W.T. is supported by a postgraduate stipend of The University of Hong Kong, and the data presented were derived from part of his PhD thesis work.

Disclosure statement: the authors have nothing to disclose.

References


Endocrinology is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.
AUTHOR PLEASE ANSWER ALL QUERIES

A—Please verify location of American Type Culture Collection, Life Technologies, and New England Biolabs.
B—Please confirm definition of MTS and BrdU.
C—Please verify location of BD Biosciences, Promega, and Roche.
D—Please define TBS-T.
E—Please verify locations of Millipore, Zymed, and Amersham Biosciences.
F—Please verify location of EG&G Berthold.
G—Please verify location of Invitrogen.
H—Please verify dNTP as written out.
I—Please verify location of Coulter Electronics and Verity Software.